

CLAIMS

1. A pharmaceutical composition comprising an oil-in-water emulsion containing a prostaglandin $F_{2\alpha}$ derivative, an oil, a water-soluble polymer and water.

2. The pharmaceutical composition according to claim 1, wherein the prostaglandin $F_{2\alpha}$ derivative is at least one member selected from latanoprost, isopropyl unoprostone, travoprost and bimatoprost.

3. The pharmaceutical composition according to claim 2, wherein the prostaglandin $F_{2\alpha}$ derivative is latanoprost.

4. The pharmaceutical composition according to claim 1, wherein the water-soluble polymer is at least one member selected from a polyvinyl compound, a water-soluble cellulose compound and a polysaccharide.

5. The pharmaceutical composition according to claim 4, wherein the polyvinyl compound is polyvinyl alcohol.

6. The pharmaceutical composition according to claim 1, wherein the oil is an animal or vegetable oil, and/or medium chain fatty acid triglyceride.

7. The pharmaceutical composition according to claim 6, wherein the medium chain fatty acid triglyceride is Miglyol.

8. The pharmaceutical composition according to any one of claims 1 to 7, wherein the pharmaceutical composition is an ophthalmological composition.

9. The pharmaceutical composition according to claim 8, wherein the ophthalmological composition is an eye drop.

10. An eye drop which is an oil-in-water emulsion, comprising latanoprost, Miglyol, polyvinyl alcohol and water.

11. A method of suppressing degradation of a prostaglandin

$F_{2\alpha}$ derivative in an emulsion, comprising blending a prostaglandin $F_{2\alpha}$ derivative, an oil, a water-soluble polymer and water to form an oil-in-water emulsion.

12. A method of suppressing degradation of latanoprost in an emulsion, comprising blending latanoprost, Miglyol, polyvinyl alcohol and water to form an oil-in-water emulsion.